AstraZeneca aims to escape drug sales trough in second half

As AstraZeneca announce their Q1 earnings Ketan Patel, fund manager at EdenTree Investment Management, commented that the jury is still out on the CEO who rebuffed a 70 billion pound offer by Pfizer.

Link

top